Clinical trials: Bone Marrow
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
This study will test the combination of clofarabine, cytarabine, and thymoglobulin as a non-myeloablative conditioning regimen for patients with myelodysplastic syndromes or acute myeloid leukemia undergoing allogeneic stem cell…
- Trial name
- NCT00593645
- Testing
- Clofarabine, Cytarabine, Thymoglobulin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
This phase II trial studies how well donor atorvastatin treatment works in preventing severe graft-versus-host disease (GVHD) after nonmyeloablative peripheral blood stem cell (PBSC) transplant in patients with hematological…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p
- Trial name
- NCT01527045
- Testing
- Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.
- Trial name
- NCT01218477
- Testing
- Dasatinib, BMS-833923
- Where
- 12 sites in United States, Canada and 5 more
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Anemia, Aplastic
Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia
Efficacy and Safety of Recombinant human thrombopoietin in patients with severe aplastic anemia and very severe aplastic anemia, a randomized, double-blind, placebo-controlled, II phase, multi-center clinical research.
- Trial name
- NCT02857530
- Testing
- rhTPO
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Tianjin Medical University General Hospital
Sexual Dysfunction
A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors
This research study is evaluating the feasibility and impact of an intervention to improve sexual function in stem cell transplant survivors on participants' sexual function, quality of life, and mood.
- Trial name
- NCT02492100
- Testing
- Multi-modality sexual dysfunction intervention
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Massachusetts General Hospital
Graft vs Host Disease
Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized.
- Trial name
- NCT00207792
- Testing
- filgrastim
- Where
- Tunisia
- Volunteers
- 160 people
- Sponsor
- Centre National de Greffe de Moelle Osseuse
Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
For the first 28 day cycle, all patients will be treated with single agent pacritinib at 200 mg twice daily. The investigators chose this starting dose based on the previous three phase I studies of pacritinib as a single agent…
- Conditions
- Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myeloproliferative Neoplasm
- Trial name
- NCT02564536
- Testing
- Pacritinib, Decitabine
- Sponsor
- Washington University School of Medicine
Myelodysplastic Syndrome (MDS)
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
Primary Outcome Measures: To evaluate the efficacy of treatment with Azacitidine in patients with transfusion-dependent, low risk International Prognostic Scoring System (IPSS) 0 int-1, Myelodysplastic Syndrome (MDS) without…
- Trial name
- ABRAZA (NCT01338337)
- Testing
- Azacitidine
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Asociación Andaluza de Hematología y Hemoterapia
Osteoarthritis, Knee, Arthritis of Knee
Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells
In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells (MSC), obtained from bone marrow of healthy donors, for treatment of knee osteoarthritis.
- Conditions
- Osteoarthritis, Knee, Arthritis of Knee, Knee Osteoarthritis
- Trial name
- MSV_allo (NCT01586312)
- Testing
- Allogenic mesenchymal stromal cells injection, Hyaluronic Acid
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Red de Terapia Celular
Acute Leukemia, Myelodysplastic Syndrome
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
- Trial name
- NCT07573111
- Testing
- QUAIL-100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Laguna Biotherapeutics, Inc.
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine
The primary purpose of this study is to evaluate the pharmacokinetics of oral azacitidine when administered once daily as two 150-mg tablets, including the effect of food, and to evaluate the bioavailability of oral azacitidine…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- NCT01519011
- Testing
- oral azacitidine
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Celgene
Dilated Cardiomyopathy
Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
A randomised, double-blind, placebo-controlled trial to evaluate the role of intracoronary injection of progenitor cells compared to placebo injection in patients with Dilated Cardiomyopathy who have been pre-treated with G-CSF…
- Trial name
- REGEN-DCM (NCT01302171)
- Testing
- granulocyte colony stimulating factor (GCSF), bone marrow mononuclear cells
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barts & The London NHS Trust
Acute Myeloid Leukemia, Myelodysplastic Syndrome
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
This is a Phase 1, uncontrolled, single-arm, open-label, nonrandomized, dose escalation, study of Decitabine (DAC)+Venetoclax (VEN)+FHD-286 in participants with newly diagnosed Acute Myeloid Leukemia (AML) classified as adverse…
- Trial name
- FHD-286 (NCT07283094)
- Testing
- Decitabine, Venetoclax, FHD-286
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Montefiore Medical Center
Multiple Myeloma (MM)
Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
This prospective, non-interventional study aims to characterize the molecular and cellular mechanisms underlying the response and resistance of multiple myeloma (MM) patients to bispecific antibodies (BisAb) and CAR-T therapies.
- Trial name
- MMOMICS (NCT06888856)
- Volunteers
- 200 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Ischemic Heart Disease, Bone Marrow Cells
Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease
The purpose of this study evaluate the effect of the method of administration of autologous bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass grafts in the surgical treatment of coronary heart…
- Conditions
- Ischemic Heart Disease, Bone Marrow Cells, Coronary Artery Bypass Grafting (CABG), Heart Failure, Diastolic
- Trial name
- TAMIS (NCT02059512)
- Testing
- Group 1, Group 0, Group 2
- Where
- Russia
- Volunteers
- 117 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Lumbar Spondylolisthesis Involving L4-L5, and/or, Degenerative Discopathy Involving L4-L5
Safety Study of Mesenchymal Stem Cells and Spinal Fusion
The present prospective, randomized study, compares the spinal fusion obtained after instrumentation and the use of a biologic product (patient's mesenchymal cells obtained from his/her own bone marrow which will be fixed in…
- Trial name
- NCT01552707
- Testing
- XCEL-MT-OSTEO-ALPHA, Standard treatment
- Where
- 5 sites in Spain
- Volunteers
- 69 people
- Sponsor
- Banc de Sang i Teixits
Myelodysplastic Syndromes
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
This is an open-label, randomized, multicenter, phase III study Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks: Either at diagnosis Or at the…
- Trial name
- EPO-PRETAR (NCT03223961)
- Testing
- EPREX
- Where
- 39 sites in France
- Volunteers
- 124 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL
Orphan Indications for CD19 Redirected Autologous T Cells
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort…
- Conditions
- Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
- Trial name
- NCT04276870
- Testing
- Murine CART19
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- Stephan Grupp MD PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.